Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the world-ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB.
Lawrence Geiter, Editor; Committee on the Elimination of Tuberculosis in the United States, Division of Health Promotion and Disease Prevention
1 Front Matter; 2 Executive Summary; 3 1 Fundamentals of Tuberculosis and Tuberculosis Control; 4 2 The Current Situation and How We Got Here; 5 3 Tuberculosis Elimination and the Changing Role of Tuberculosis Control Programs; 6 4 Advancing Toward Elimination; 7 5 Developing the Tools for Tuberculosis Elimination; 8 6 The U.S. Role in Global Tuberculosis Control; 9 7 Mobilizing for Elimination; 10 Appendix A Statement of Task; 11 Appendix B Public Session Agendas; 12 Appendix C Site Visit Summaries; 13 Appendix D Role of Public Health Laboratories in the Control of Tuberculosis; 14 Appendix E Estimating the Number of Tuberculosis Cases That Can Be Prevented by a Program of Screening and Preventive Therapy of Newly Arrived Immigrants to the United States from Countries with a High Rate of Tuberculosis a; 15 Appendix F Approval Dates for Existing and Prospects for Development of New Antituberculosis Drugs and Vaccines; 16 Appendix G Committee Biographies; 17 Index
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie McCormick, Padma Shetty, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Theresa Wizemann, Donna A. Alamario, Kathleen Stratton
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on a National Strategy for the Elimination of Hepatitis B and C, Brian L. Strom, Gillian J. Buckley
Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee to Study Priorities for Vaccine Development, Robert S. Lawrence, Jane S. Durch, Kathleen R. Stratton
Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Care Services, Committee on Immunization Finance Policies and Practices
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Christopher B. Wilson, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Care Services, Committee on Immunization Finance Policies and Practices
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Theresa M. Wizemann, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Board on Population Health and Public Health Practice, Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie McCormick, Padma Shetty, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Phase II Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Rino Rappuoli, Dennis Fryback, Charles Phelps, Kinpritma Sangha, Guruprasad Madhavan
National Academy of Engineering, Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Phase III Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Rino Rappuoli, Charles Phelps, Guruprasad Madhavan
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Donna A. Almario, Kathleen Stratton